Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Varex Imaging (VREX): Assessing the Path Toward $22

Varex Imaging (VREX): Assessing the Path Toward $22

Key Takeaways

  • The $22 level discussed here is a publicly referenced price objective rather than a current analyst consensus, as recent targets sit too close to the market price to provide meaningful separation.
  • The latest verified share price is approximately $18.10, implying that reaching $22 would require a roughly 21.5% advance.
  • Current analyst targets cluster tightly near $18.90 to $19.00, producing a consensus rating of Hold with no Buy or Sell ratings among the four analysts tracked.
  • The stock has more than doubled from its 52-week low of $9.09 and trades just below the 52-week high of $18.63.
  • Positive drivers include solid revenue growth, strength in CT and cargo systems, and momentum in photon-counting detectors.
  • Key risks center on the heavy downgrade cycle in August 2026, margin pressure, and the sustainability of demand in a cyclical industrial market.
  • Additional context is available through the Major News, Today's Price Move, Forecast, and Earnings pages for VREX.
  • Readers can also review Trending AI Robots to observe how AI-driven strategies are evaluating opportunities across the broader market.

Setting the $22 Benchmark

Recent sell-side targets sit at roughly $18.90 to $19.00, only 4% to 5% above the latest price, so no aggregate analyst target clears a 10% threshold above the market. Four analysts tracked by TipRanks produce an average near $18.92 within a narrow range of $18.90 to $19.00 and a Hold consensus. That average does not offer a useful benchmark above the current price.

This discussion therefore uses a publicly referenced price objective. The $22 level draws from the upper end of ranges cited by market data aggregators, where the median has appeared near $20 and the high near $23, and it aligns with Sidoti’s earlier initiation target of $22. It serves as a discussion benchmark rather than a published Street consensus or formal forecast.

Current Positioning and the Route to the Target

At approximately $18.10, a move to $22 represents about 21.5% upside—a meaningful advance rather than a modest step. The path would first require clearing the 52-week high of $18.63, followed by the $20 round number before approaching $22. Varex has already delivered a year-to-date gain exceeding 55%, indicating that much of the recovery from the May 2026 low near $9 has already taken place.

On the fundamentals, first-quarter fiscal 2026 revenue reached $210 million, up 5% year over year, while second-quarter revenue was $216 million. Management has pointed to ongoing momentum in global CT, cargo systems, and photon-counting detectors. Results and guidance have generally met or exceeded expectations, yet the stock’s trailing P/E near 34 already embeds expectations of further improvement. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Factors That Could Support Further Gains

  • Steady revenue growth tied to global CT demand, cargo inspection systems, and photon-counting detector adoption.
  • Debt refinancing completed in March 2026, which delivered a $490 million credit facility and extended maturities to 2031, enhancing financial flexibility.
  • A diversified Medical and Industrial presence that can help balance weakness in any single end market.
  • A forward P/E below the trailing P/E, consistent with expectations for improving EPS.

Obstacles That Could Limit Upside

  • The broad August 2026 downgrade wave, with CJS Securities, Oppenheimer, B. Riley Securities, and Sidoti shifting to Hold or equivalent ratings amid questions about growth durability and risk-reward balance.
  • Margin pressure and cyclical exposure in the industrial segment, where demand can soften rapidly.
  • Thin trailing profitability, with GAAP results alternating between modest profits and losses in recent quarters.
  • Potential valuation compression if growth expectations do not materialize, given a trailing P/E above 30.

Technical Markers and Market Structure

The key technical references remain the 52-week high of $18.63 and the 52-week low of $9.09. Trading just below $18.63, that level serves as near-term resistance. A sustained break above it would bring the $20 psychological level into view, with $22 as the subsequent objective. On the downside, the $17 to $18 zone has functioned as a recent consolidation area. From what I see, watching how volume develops around these levels will be useful.

Time Horizon and Items to Watch

Analyst targets typically reflect a roughly 12-month horizon, though individual firms vary. Investors should monitor upcoming quarterly results and fiscal 2027 guidance, shifts in CT and cargo-system order trends, any changes to analyst targets, and progress on margins and free cash flow. Given relatively light coverage and clustered targets, a single upgrade or target increase could move sentiment noticeably.

Integrating AI Tools for Ongoing Monitoring

I frequently review Tickeron’s AI Daily Buy/Sell Signals as a data-driven complement to fundamental work. The system applies artificial intelligence to evaluate market behavior and technical patterns across thousands of stocks and ETFs, producing Buy, Sell, or Hold signals that help track shifting conditions and spot potential changes in trend more efficiently. I incorporate these signals alongside my own analysis to stay attuned to evolving dynamics without replacing core research.

Overall Perspective

Can Varex Imaging stock reach $22? The level sits a substantial 21.5% above the recent price and is best viewed as a publicly discussed objective rather than a firm analyst target. Revenue momentum, diversified end markets, and the refinanced balance sheet provide a reasonable foundation, yet the August 2026 downgrade cycle, thin GAAP profitability, and proximity to the 52-week high present tangible hurdles. The decisive test will be whether VREX can break and hold above $18.63 and then $20, developments best evaluated against upcoming earnings, guidance, and any shift in analyst views. No outcome is assured, and the target functions as a monitoring framework rather than a prediction.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: VREX

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


VREX in downward trend: 10-day moving average moved below 50-day moving average on November 10, 2026

The 10-day moving average for VREX crossed bearishly below the 50-day moving average on November 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VREX as a result. In 61 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.

VREX moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VREX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.

The Aroon Indicator for VREX entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +0.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where VREX advanced for three days, in 195 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.

VREX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. VREX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.577) is normal, around the industry mean (4.142). P/E Ratio (34.148) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (4.979) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.903) is also within normal values, averaging (40.124).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VREX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -9%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -14%. POAS experienced the highest price growth at 172%, while LFWD experienced the biggest fall at -46%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -44%. For the same stocks of the Industry, the average monthly volume growth was -3% and the average quarterly volume growth was -49%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 62
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 14 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufactures of X-ray tubes, flat panel detectors, connectors and accessories for imaging as well as workstations and software for computer-aided diagnostics and image processing

Industry MedicalNursingServices

Industry
Medical Specialties
Address
1678 S. Pioneer Road
Phone
+1 801 972-5000
Employees
2400
Web
https://www.vareximaging.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.